SG11202100014RA - Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 - Google Patents
Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1Info
- Publication number
- SG11202100014RA SG11202100014RA SG11202100014RA SG11202100014RA SG11202100014RA SG 11202100014R A SG11202100014R A SG 11202100014RA SG 11202100014R A SG11202100014R A SG 11202100014RA SG 11202100014R A SG11202100014R A SG 11202100014RA SG 11202100014R A SG11202100014R A SG 11202100014RA
- Authority
- SG
- Singapore
- Prior art keywords
- cx3cl1
- cx3cr1
- thiazolo
- pyrimidines
- thio
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811169.0A GB201811169D0 (en) | 2018-07-06 | 2018-07-06 | New compounds |
| PCT/EP2019/068169 WO2020008064A1 (en) | 2018-07-06 | 2019-07-05 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100014RA true SG11202100014RA (en) | 2021-01-28 |
Family
ID=63273083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100014RA SG11202100014RA (en) | 2018-07-06 | 2019-07-05 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20210292349A1 (ko) |
| EP (1) | EP3818065B1 (ko) |
| KR (1) | KR20210032403A (ko) |
| CN (1) | CN112867725A (ko) |
| AU (1) | AU2019297572A1 (ko) |
| CA (1) | CA3105566A1 (ko) |
| CY (1) | CY1126070T1 (ko) |
| DK (1) | DK3818065T3 (ko) |
| ES (1) | ES2945561T3 (ko) |
| FI (1) | FI3818065T3 (ko) |
| GB (1) | GB201811169D0 (ko) |
| HR (1) | HRP20230532T1 (ko) |
| HU (1) | HUE062011T2 (ko) |
| IL (1) | IL279818B2 (ko) |
| LT (1) | LT3818065T (ko) |
| MX (1) | MX2021000011A (ko) |
| PL (1) | PL3818065T3 (ko) |
| PT (1) | PT3818065T (ko) |
| SG (1) | SG11202100014RA (ko) |
| SI (1) | SI3818065T1 (ko) |
| WO (1) | WO2020008064A1 (ko) |
| ZA (1) | ZA202100192B (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| MXPA05013628A (es) * | 2003-06-27 | 2006-02-24 | Pfizer Prod Inc | Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3. |
| BRPI0415050A (pt) | 2003-10-07 | 2006-11-28 | Astrazeneca Ab | composto, formulação farmacêutica, método para tratar ou reduzir risco de uma doença ou condição humanas, uso de um composto ou de um sal deste farmaceuticamente aceitável, e, processo para a preparação de um composto ou de um sal deste farmaceuticamente aceitável |
| ATE417830T1 (de) * | 2004-11-02 | 2009-01-15 | Pfizer | Sulfonylbenzimidazolderivate |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| PL2038290T3 (pl) | 2006-07-07 | 2014-03-31 | Gilead Sciences Inc | Modulatory receptora Toll-podobnego 7 |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| CA2664930A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Novel 5,7-disubstituted[1,3]thiazolo[4,5-d]pyrimidin-2(3h)-amine derivatives and their use in therapy |
| CN101516893B (zh) * | 2006-09-29 | 2011-11-30 | 阿斯利康(瑞典)有限公司 | 5,7-二取代的[1,3]噻唑并[4,5-d]嘧啶-2(3h)-酮衍生物和它们在治疗中的用途 |
| JP5562865B2 (ja) * | 2007-12-17 | 2014-07-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター |
| AR071036A1 (es) * | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
| WO2011139348A2 (en) * | 2010-04-30 | 2011-11-10 | The Regents Of The University Of California | Uses of phospholipid conjugates of synthetic tlr7 agonists |
| CN104640444B (zh) * | 2012-06-16 | 2016-12-14 | 河南美泰宝生物制药有限公司 | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 |
| WO2016200939A1 (en) | 2015-06-08 | 2016-12-15 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
-
2018
- 2018-07-06 GB GBGB1811169.0A patent/GB201811169D0/en not_active Ceased
-
2019
- 2019-07-05 WO PCT/EP2019/068169 patent/WO2020008064A1/en unknown
- 2019-07-05 PT PT197392343T patent/PT3818065T/pt unknown
- 2019-07-05 PL PL19739234.3T patent/PL3818065T3/pl unknown
- 2019-07-05 HU HUE19739234A patent/HUE062011T2/hu unknown
- 2019-07-05 CA CA3105566A patent/CA3105566A1/en active Pending
- 2019-07-05 US US17/257,917 patent/US20210292349A1/en active Pending
- 2019-07-05 DK DK19739234.3T patent/DK3818065T3/da active
- 2019-07-05 ES ES19739234T patent/ES2945561T3/es active Active
- 2019-07-05 SG SG11202100014RA patent/SG11202100014RA/en unknown
- 2019-07-05 FI FIEP19739234.3T patent/FI3818065T3/fi active
- 2019-07-05 MX MX2021000011A patent/MX2021000011A/es unknown
- 2019-07-05 CN CN201980057603.6A patent/CN112867725A/zh active Pending
- 2019-07-05 IL IL279818A patent/IL279818B2/en unknown
- 2019-07-05 EP EP19739234.3A patent/EP3818065B1/en active Active
- 2019-07-05 SI SI201930537T patent/SI3818065T1/sl unknown
- 2019-07-05 AU AU2019297572A patent/AU2019297572A1/en active Pending
- 2019-07-05 LT LTEPPCT/EP2019/068169T patent/LT3818065T/lt unknown
- 2019-07-05 KR KR1020217003104A patent/KR20210032403A/ko not_active Application Discontinuation
- 2019-07-05 HR HRP20230532TT patent/HRP20230532T1/hr unknown
-
2021
- 2021-01-12 ZA ZA2021/00192A patent/ZA202100192B/en unknown
- 2021-07-09 US US17/372,125 patent/US11339183B2/en active Active
-
2023
- 2023-06-15 CY CY20231100281T patent/CY1126070T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1126070T1 (el) | 2023-11-15 |
| MX2021000011A (es) | 2021-05-12 |
| KR20210032403A (ko) | 2021-03-24 |
| DK3818065T3 (da) | 2023-05-15 |
| JP2021530474A (ja) | 2021-11-11 |
| US20210340167A1 (en) | 2021-11-04 |
| IL279818B2 (en) | 2024-06-01 |
| US20210292349A1 (en) | 2021-09-23 |
| EP3818065B1 (en) | 2023-03-15 |
| PL3818065T3 (pl) | 2023-10-09 |
| ES2945561T3 (es) | 2023-07-04 |
| PT3818065T (pt) | 2023-05-30 |
| FI3818065T3 (fi) | 2023-06-13 |
| HRP20230532T1 (hr) | 2023-08-04 |
| CA3105566A1 (en) | 2020-01-09 |
| GB201811169D0 (en) | 2018-08-29 |
| IL279818A (en) | 2021-03-01 |
| SI3818065T1 (sl) | 2023-08-31 |
| HUE062011T2 (hu) | 2023-09-28 |
| WO2020008064A1 (en) | 2020-01-09 |
| AU2019297572A1 (en) | 2021-01-28 |
| EP3818065A1 (en) | 2021-05-12 |
| CN112867725A (zh) | 2021-05-28 |
| LT3818065T (lt) | 2023-06-26 |
| US11339183B2 (en) | 2022-05-24 |
| ZA202100192B (en) | 2023-07-26 |
| IL279818B1 (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246564A (en) | 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases | |
| MX2019005834A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2. | |
| ZA202100192B (en) | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| MY191016A (en) | 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors | |
| NZ751284A (en) | Novel jak1 selective inhibitors and uses thereof | |
| MX2017002271A (es) | Composiciones y metodos para el tratamiento de trastornos neurologicos. | |
| IL246579B (en) | Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease | |
| MY176142A (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| SG10201908697XA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| EP3215509A4 (en) | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | |
| MX2015013945A (es) | Derivados de urea utiles como inhibidores de quinasa. | |
| IL262177B (en) | Pyrimidinyl Carboxamide, 5-a] compounds and their use for the treatment of medical disorders | |
| AU2017261291A1 (en) | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | |
| MX2022007994A (es) | Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos. | |
| MX2019004070A (es) | Sistema de extraccion de un sistema de circuito cerrado. | |
| EP3452480A4 (en) | SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
| MX2021007260A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales. | |
| MX2019012176A (es) | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. | |
| EP3344632A4 (en) | Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders | |
| DK3292867T3 (da) | Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion | |
| UA118278C2 (uk) | Гідроксиформамідні похідні та їх застосування | |
| MX2021015628A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. | |
| NZ756936A (en) | Composition and method for preventing or delaying onset of myopia comprising atropine |